

ZYMUTEST β 2GPI

ARK022A

(Complete ELISA kit for measuring human β 2GPI Antigen)

For in vitro research use only



Manufactured By: HYPHEN BioMed

Last revision: 05/12/2007

INTENDED USE:

The ZYMUTEST β 2GPI kit is an immuno-assay for measuring human Beta 2 Glycoprotein I (β 2GPI) in plasma, or in any fluid where β 2GPI can be present.

ASSAY PRINCIPLE:

The ZYMUTEST β 2GPI is a one step enzyme immuno-assay for the measurement of β 2GPI in plasma or biological milieu. First, the immunoconjugate, a goat polyclonal antibody, specific for human β 2GPI, and coupled to horse-radish-peroxidase (HRP), is introduced into the microwell, coated with a polyclonal antibody specific for β 2GPI. Then, the diluted test sample is introduced and the immunological reaction starts. When present, β 2GPI binds to the coated microwell and reacts with the immunoconjugate, simultaneously. Following a washing step, the peroxidase substrate, tetramethylbenzidine (TMB) in presence of hydrogen peroxide (H₂O₂), is introduced and a blue colour develops. The colour turns yellow when the reaction is stopped with Sulfuric Acid. The amount of colour developed is directly proportional to the concentration of β 2GPI in the tested sample.

TEST SAMPLE:

- Trisodium Citrate or Na₂ EDTA anticoagulated human plasma.
- The assay can be performed on serum.
- Any biological fluid where β 2GPI:Ag must be measured.

REAGENTS:

1. **COAT:** Micro ELISA plate, containing 12 strips of 8 wells, coated with highly purified polyclonal antibodies specific for human β 2GPI, then stabilised; the plate is packed in an aluminium pouch hermetically sealed in presence of a desiccant.
2. **SD:** 2 vials containing 60ml of B2F-Sample Diluent, ready to use.
3. **STD:** 3 vials of β 2GPI Calibrator, lyophilised. When restored with 2 ml of B2F-Sample Diluent, a solution containing "C" ng/ml of human β 2GPI is obtained.
4. **CI:** 1 vial containing 1 ml of lyophilised (h) β 2GPI Control I (High).
5. **CI:** 1 vial containing 1 ml of lyophilised (h) β 2GPI Control II (Low).

Note: The β 2GPI concentrations and acceptancy ranges for calibrator and controls can vary from lot to lot, but are precisely indicated for each lot on the flyer provided in the kit.

6. **IC:** 3 vials of Anti-(h)- β 2GPI-HRP immunoconjugate, a polyclonal antibody coupled to HRP, lyophilised.
7. **CD:** 1 vial of 25 ml of B2F-Conjugate Diluent, ready to use.
8. **WS:** 1 vial of 50 ml of 20 fold concentrated Wash Solution.
9. **TMB:** 1 vial of 25 ml peroxidase substrate: 3,3',5,5' - Tetramethylbenzidine containing hydrogen peroxide. Ready to use.
10. **SA:** 1 vial of 6 ml of 0.45M Sulfuric acid (Stop solution). Ready to use.

Note: Use only components from a same kit lot. Do not mix components from different lots of kits, when running the assay.

REAGENTS AND EQUIPMENT REQUIRED BUT NOT PROVIDED:

- 8-channel or repeating pipette allowing dispensing 50-300 μ l.
- 1-channel pipettes at variable volumes from 0 to 20 μ l, 20 to 200 μ l and 200 to 1000 μ l.
- Micro ELISA plate washing equipment and shaker.
- Micro ELISA plate reader with a wavelength set up at 450 nm.
- Distilled water.

REAGENTS PREPARATION, STORAGE AND STABILITY:

In their original packaging box, before use, when stored at 2-8°C, the unopened reagents are stable until the expiration date printed on the box.

1. **Micro ELISA plate:** open the plastic pouch and take off the required amounts of 8 well strips for the test series. When out of the pouch, the strips must be used within 30 minutes. Unused strips can be stored at 2-8°C for 4 weeks in their original

aluminium pouch, in presence of the desiccant, hermetically closed and protected from any moisture, and stored in the provided microplate storage bag (minigrp).

2. **B2F-Sample Diluent:** It is ready to use. When open, it can be used for 4 weeks, stored at 2-8 °C, and provided that any bacterial contamination is avoided during use. This reagent contains 0.05% Kathon CG.
3. **β 2GPI Calibrator:** restore each vial with 2 ml of B2F-Sample Diluent in order to obtain a solution containing "C" ng/ml of β 2GPI. This solution is stable for at least 8 hours at room temperature (18-25°C) or 72 hours at 2-8°C.
4. **β 2GPI Control I (high):** restore with 1 ml of B2F-Sample Diluent.
5. **β 2GPI Control II (low):** restore with 1 ml of B2F-Sample Diluent.

Note: when restored, β 2GPI controls are stable for 8 hours at room temperature, 72 hours at 2-8°C or 2 months frozen at -20°C or below.

Warning: Purified (h) β 2GPI used for the preparation of calibrator (3) and controls (4&5) is prepared with normal human plasma. This latter was tested with registered methods and found negative for HIV antibodies, HBs Ag and HVC antibodies. However, no assay may warrant the total absence of infectious agents. Any product of human origin must then be handled with all the required cautions, as being potentially infectious.

6. **Anti-(h)- β 2GPI-HRP immunoconjugate:** each vial must be restored with 7.5 ml of B2F-Conjugate Diluent. Let the pellet to be completely dissolved before use, and shake the vial gently in order to homogenize the content. The restored conjugate is stable for at least 24 hours at room temperature or for at least 4 weeks at 2-8°C.
7. **B2F-Conjugate Diluent:** It is ready to use. When open, it can be used for 4 weeks, stored at 2-8 °C, and provided that any bacterial contamination is avoided during use. This reagent contains 0.05% Kathon CG.
8. **Wash Solution:** Incubate the vial for 15-30 minutes in a water bath at 37°C until complete dissolution of solids, when present. Shake the vial and dilute the amount required 1:20 in distilled water (the 50 ml contained in the vial allow preparing 1 liter of Wash Solution). The Wash Solution must be stored at 2-8°C in its original vial and used within 4 weeks following opening. The diluted Wash Solution must be used within 7 days, when protected from any contamination and stored at 2-8°C. This reagent contains 0.05% Kathon CG.
9. **TMB substrate:** It is ready to use. When open, it can be used for 4 weeks, stored at 2-8°C, and provided that any bacterial contamination is avoided during use.
10. **Stop solution:** It is ready to use.

Cautions: Sulfuric acid, although diluted to 0.45M is caustic. As for any similar chemical, handle Sulfuric acid with great care. Avoid any skin and eye contact. Wear protection glasses and gloves when handling.

Note: Bring the kit at room temperature, at least 30 min. before use. Store the unused reagents at 2-8°C. The stability studies at 30°C show that the reagents can be shipped at room temperature without damage.

PROCEDURE:

Specimen collection:

Blood (9 vol.) must be collected on 0.109M citrate anticoagulant (1 vol.) by a clean venipuncture; plasma supernatant is decanted following a 20 min. centrifugation at 2,500 g; citrated plasma should be tested within 8 hours or stored frozen at -20°C or below for up to 6 months, and thawed for 15 min. at 37°C just before use. Thawed specimen must be tested within 4 hours.

EDTA collected human plasma may also be used. Conditions of storage are the same than those for citrated plasma.

Tested plasma or sample or controls:

- The sample must be tested diluted in order to obtain a concentration < 100ng/ml in the B2F-Sample Diluent.

For example, a human plasma must be tested at the 1:4,000 dilution in the B2F-Sample Diluent (SD).

For an improved accuracy, when high dilutions are required, proceed by successive dilutions as follows:

Add 20 μ l of plasma into 180 μ l of B2F-Sample Diluent (D=1:10); mix for homogenising. Then add 20 μ l if this « 1:10 dilution » into 180 μ l of B2F-Sample Diluent (D=1:10); mix for homogenising (D=1:100 final).

Then add 20 μ l of this « 1:100 dilution » into 780 μ l of B2F-Sample Diluent (D=1:40); mix for homogenising. It allows obtaining a final dilution of 1:4,000 for the assayed sample

D.750.02/ZY/022A



6560 Gove Court - Mason, OH 45040

Phone: 513.770.1991

Toll Free: 866.783.3797

Fax: 513.573.9241

Email: info@aniara.com

www.aniara.com

Controls I & II, restored with 1ml of B2F-Sample Diluent (SD), are already diluted 1:4,000 before lyophilisation and must then be tested "undiluted".

- For tested specimen different from plasma, adjust the assayed dilution according to the expected β 2GPI concentration, in order to have this latter within the dynamic range, ie 5 to 100 ng/ml. In order to avoid any matrix effect, use at least a 1:5 dilution in the B2F-sample diluent (SD)

Calibration:

Using the "C" ng/ml β 2GPI calibrator provided in the kit, prepare the following standard solutions.

β 2GPI concentration (ng/ml)	C	C:2	C:4	C:10	C:20	0
Vol. of β 2GPI calibrator	1 ml	0.5 ml	0.25 ml	0.1 ml	0.05 ml	0 ml
Vol. of B2F- Sample Diluent	0 ml	0.5 ml	0.75 ml	0.9 ml	0.95 ml	1 ml

Mix gently for a complete homogenisation.

The standard dilutions are stable for at least 4 hours at room temperature.

Assay procedure:

Remove the required number of strips from the aluminium pouch, for the series of measures to be performed. Then put the strips in the frame provided. In the different wells of the micro ELISA plate introduce the reagents and perform the various assay steps as indicated on the following table:

Reagent	Volume	Procedure
Conjugate (anti β 2GPI antibody coupled with peroxidase; restored with 7.5 ml of B2F-Conjugate Diluent)	200 μ l	Introduce the Anti-(h)- β 2GPI- HRP immunoconjugate in the micro ELISA plate wells
β 2GPI standards (1:1), or tested sample diluted 1:4,000, or controls (1:1), or B2F-Sample Diluent (blank)	50 μ l	Introduce the standard solutions or the tested samples in the corresponding micro ELISA plate well (a).
Incubate for 1 hour at room temperature (18-25°C) (b)		
Wash Solution (20 fold diluted in distilled water)	300 μ l	Proceed to 5 successive washings using the washing instrument (b).
TMB/H ₂ O ₂ Substrate	200 μ l	Immediately after the washing, introduce the substrate into the wells. Note: The substrate distribution, row by row, must be accurate and at exact time intervals (c, d).
Incubate for exactly 5 minutes at room temperature (18-25 °C) (b)		
0.45M Sulfuric Acid	50 μ l	Following exactly the same time intervals than for the addition of substrate, stop the colour development by introducing the 0.45M sulfuric acid.
Wait for 10 minutes in order to allow the colour to stabilize and measure absorbance at 450 nm (A450) (e). Subtract the blank values		

Note:

- Distribute calibrators, controls and tested specimen as rapidly as possible (within 10 minutes), in order to obtain an homogeneous immunological kinetics for β 2GPI binding.
- Avoid letting the plate in the bright sunlight during incubations and more particularly during colour development. A micro-ELISA plate shaker can be used.
- Never let the plates empty between the addition of the reagents or following the washing step. The next reagent must be added within 3 minutes, in order to prevent the plate from drying, which could damage the immobilized components. If necessary, keep the plate filled with Wash Solution and empty it just before the introduction of the next reagent. The washing instrument must be adjusted in order to wash the plates gently, and to avoid a too drastic emptying, which could lower plate reactivity.
- For addition of the TMB substrate, the time interval between each row must be accurate and exactly determined. It must be the same when stopping the reaction.
- For bichromatic readings, a reference wavelength at 690 nm or at 620 nm can be used.

EXPRESSION OF RESULTS:

- On a linear graph paper plot the β 2GPI:Ag concentrations, in ng/ml, on abscissa and the corresponding absorbances (A450) on ordinates (See model on the flyer).
- Users must construct their own calibration curve, obtained using their standard dilutions. From the curve obtained, deduce the β 2GPI:Ag concentration for the diluted tested sample. For obtaining the β 2GPI concentration in this undiluted sample, this value must be **multiplied by the dilution factor used** (ex: 4,000...).
- For controls I and II, the concentrations measured are directly deduced from the curve.
- Alternatively, an ELISA software (i.e. Dynex, Biolise, etc...) can be used for the calculation of concentrations.

EXPECTED RANGE:

The expected β 2GPI:Ag concentration in normal human plasma is of about 200 μ g/ml (about 180 \pm 100 μ g/ml determined with Zymutest β 2GPI kit).

BIOCHEMISTRY:

β 2GPI (Beta 2- glycoprotein I, also called apolipoprotein H) is a 50 kDa plasma glycoprotein, with a high affinity for negatively charged phospholipid surfaces. Its physiological role remains unclear; however β 2GPI shows a variety of anticoagulant properties in vitro, by interfering with the anionic phospholipid surfaces onto coagulation processes are focused.

PATHOLOGICALS VARIATIONS:

β 2GPI concentration in plasma seems to be reduced in various increased coagulation clinical contexts, in patients with disseminated intravascular coagulation; however any association of this decrease as a risk factor for thrombotic risk is still discussed.

Auto-antibodies to β 2GPI are usually absent in normal population. Their presence at moderate or high concentrations can be associated with recurrent abortions, miscarriages or with the anti-phospholipid syndrome (APS), sometimes associated with thrombotic diseases.

APPLICATIONS:

Assay of β 2GPI :Ag in clinical plasma samples.

Measurement of β 2GPI :Ag in biological fluids in research studies.

ASSAY CHARACTERISTICS:

- Detection threshold \leq 5 ng/ml (directly read on the curve).
- Intra-assay CV: 3-8%.
- Inter-assay CV: 5-10%.
- Reference material: The β 2GPI calibrator of the ZYMUTEST β 2GPI kit is established against a normal citrated plasma pool, and against highly purified human β 2GPI, which protein concentration has been precisely determined by Lowry.

REFERENCES:

- "Coagulation and fibrinolytic activities in 2 siblings with β -glycoprotein I deficiency", Rie Takeuchi, Tatsuya Atsumi, Masahiro Ieko, Hiroyuki Takeya, Shinsuke Yasuda, Kenji Ichikawa, Akito Tsutsumi, Koji Suzuki, Takao Koike, *Blood*, 96(4):1594-1595, 2000.
- "Clinical significance of anti- β -Glycoprotein I antibodies", Amengual O., Atsumi T., Khamashta M.A., Hughes G.R.V., *Am. Med. Interne*, 147(1):15-17, 1997.
- "Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant", Brighton TH, Hogg PJ, Dai YP, Murray BH, Chong BH, Chersterman CN, *Br J Haematol*, 93(1):185-94, 1996.
- "Beta 2-glycoprotein I deficiency and the risk of thrombosis", Bancsi LF, van der Linden IK, Bertina RM, *Thromb Haemost*, 67(6):649-53, 1992.